ES2277085T3 - Nuevos esteres de etonogestrel. - Google Patents
Nuevos esteres de etonogestrel. Download PDFInfo
- Publication number
- ES2277085T3 ES2277085T3 ES03735713T ES03735713T ES2277085T3 ES 2277085 T3 ES2277085 T3 ES 2277085T3 ES 03735713 T ES03735713 T ES 03735713T ES 03735713 T ES03735713 T ES 03735713T ES 2277085 T3 ES2277085 T3 ES 2277085T3
- Authority
- ES
- Spain
- Prior art keywords
- etonogestrel
- female
- tsh
- contraception
- male
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical class O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 title claims abstract description 107
- 229960002941 etonogestrel Drugs 0.000 claims abstract description 104
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims abstract description 20
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims abstract description 19
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 206010027295 Menometrorrhagia Diseases 0.000 claims description 4
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
- 239000003433 contraceptive agent Substances 0.000 claims description 4
- 230000002254 contraceptive effect Effects 0.000 claims description 4
- 208000007106 menorrhagia Diseases 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- -1 1-oxononyl Chemical group 0.000 description 8
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 8
- 239000000583 progesterone congener Substances 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 6
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 5
- 150000003509 tertiary alcohols Chemical class 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-M pentadecanoate Chemical compound CCCCCCCCCCCCCCC([O-])=O WQEPLUUGTLDZJY-UHFFFAOYSA-M 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 3
- 230000021595 spermatogenesis Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000004451 Pituitary Gonadotropins Human genes 0.000 description 1
- 108010081865 Pituitary Gonadotropins Proteins 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 239000002583 male contraceptive agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0096—Alkynyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077119 | 2002-05-30 | ||
| EP02077119 | 2002-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2277085T3 true ES2277085T3 (es) | 2007-07-01 |
Family
ID=29595014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03735713T Expired - Lifetime ES2277085T3 (es) | 2002-05-30 | 2003-05-22 | Nuevos esteres de etonogestrel. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7323454B2 (enExample) |
| EP (1) | EP1513861B1 (enExample) |
| JP (1) | JP4716726B2 (enExample) |
| KR (1) | KR20050009723A (enExample) |
| CN (2) | CN101100480A (enExample) |
| AR (1) | AR040130A1 (enExample) |
| AT (1) | ATE349458T1 (enExample) |
| AU (1) | AU2003238081B2 (enExample) |
| BR (1) | BR0311254A (enExample) |
| CA (1) | CA2487722C (enExample) |
| CO (1) | CO5631449A2 (enExample) |
| DE (1) | DE60310714T2 (enExample) |
| DK (1) | DK1513861T3 (enExample) |
| ES (1) | ES2277085T3 (enExample) |
| HR (1) | HRP20041101A2 (enExample) |
| IL (1) | IL165087A0 (enExample) |
| IS (1) | IS2421B (enExample) |
| MX (1) | MXPA04011797A (enExample) |
| NO (1) | NO20044898L (enExample) |
| NZ (1) | NZ536619A (enExample) |
| PE (1) | PE20040068A1 (enExample) |
| PL (1) | PL373855A1 (enExample) |
| PT (1) | PT1513861E (enExample) |
| RS (1) | RS97604A (enExample) |
| RU (1) | RU2325910C2 (enExample) |
| SI (1) | SI1513861T1 (enExample) |
| TW (1) | TW200403065A (enExample) |
| UA (1) | UA80126C2 (enExample) |
| WO (1) | WO2003102012A2 (enExample) |
| ZA (1) | ZA200410410B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200400041A (en) * | 2002-05-30 | 2004-01-01 | Akzo Nobel Nv | Use of new etonogestrel esters |
| US20090062909A1 (en) | 2005-07-15 | 2009-03-05 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
| EP1909973B1 (en) | 2005-07-15 | 2018-08-22 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
| CA2996768C (en) | 2006-04-26 | 2020-12-08 | Micell Technologies, Inc. | Coatings containing multiple drugs |
| US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
| CN101711137B (zh) | 2007-01-08 | 2014-10-22 | 米歇尔技术公司 | 具有可生物降解层的支架 |
| US9433516B2 (en) | 2007-04-17 | 2016-09-06 | Micell Technologies, Inc. | Stents having controlled elution |
| SG192524A1 (en) | 2008-04-17 | 2013-08-30 | Micell Technologies Inc | Stents having bioabsorbable layers |
| CA2730995C (en) | 2008-07-17 | 2016-11-22 | Micell Technologies, Inc. | Drug delivery medical device |
| WO2010111232A2 (en) | 2009-03-23 | 2010-09-30 | Micell Technologies, Inc. | Drug delivery medical device |
| CA2757276C (en) | 2009-04-01 | 2017-06-06 | Micell Technologies, Inc. | Coated stents |
| EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | MEDICAL DEVICE DISPENSING MEDICINE |
| US11369498B2 (en) | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
| CA2797110C (en) | 2010-04-22 | 2020-07-21 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
| WO2012009684A2 (en) | 2010-07-16 | 2012-01-19 | Micell Technologies, Inc. | Drug delivery medical device |
| WO2013012689A1 (en) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Drug delivery medical device |
| US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
| CN110269959A (zh) | 2013-03-12 | 2019-09-24 | 脉胜医疗技术公司 | 可生物吸收的生物医学植入物 |
| AU2014265460B2 (en) | 2013-05-15 | 2018-10-18 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
| RU2595818C1 (ru) * | 2015-05-25 | 2016-08-27 | Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" | Способ комплексного лечения дисфункции яичников при применении гормонального контрацептива имплантата "импланона" |
| CN111057120B (zh) * | 2019-12-27 | 2021-04-27 | 苏州翔实医药发展有限公司 | 一种依托孕烯衍生物a及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1013284B (de) | 1956-03-22 | 1957-08-08 | Schering Ag | Verfahren zur Einfuehrung der Reste wenig reaktionsfaehiger Carbonsaeuren, insbesondere des ª‰-Cyclopentyl-propionylrestes, in die 17ª‡-staendige Oxygruppe solcher Steroide, die am Kohlenstoffatom 17 neben der Oxygruppe eine Acetylgruppe tragen |
| GB845442A (en) | 1956-03-22 | 1960-08-24 | Schering Ag | Manufacture of steroid compounds |
| GB8313921D0 (en) * | 1983-05-19 | 1983-06-22 | World Health Org | Contraceptive compositions |
| DE4227989A1 (de) | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
| DE4240806A1 (de) | 1992-12-01 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol |
| JPH07101884A (ja) | 1993-10-01 | 1995-04-18 | Sanei Gen F F I Inc | 水溶性ヘミセルロースを含有する製剤 |
| AU692504B2 (en) | 1993-12-27 | 1998-06-11 | Akzo Nobel N.V. | Percutaneously absorbable preparation |
| WO1997003709A1 (de) * | 1995-07-17 | 1997-02-06 | Schering Aktiengesellschaft | Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel |
| DE19613698A1 (de) | 1995-07-17 | 1997-01-23 | Schering Ag | Mittel zur transdermalen Applikation enthaltend Ester des 13-Ethyl-17ß-hydroxy-11-methylen-18,19-dinor-17alpha-pregn-4-en-20-yn-3-ons |
| DE19531936A1 (de) * | 1995-08-17 | 1997-02-20 | Schering Ag | Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend |
| DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
| WO1999067271A1 (en) | 1998-06-19 | 1999-12-29 | Akzo Nobel N.V. | Testosterone derivative |
| WO1999067270A1 (en) | 1998-06-19 | 1999-12-29 | Akzo Nobel N.V. | Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone) |
| US6180682B1 (en) | 1999-01-26 | 2001-01-30 | Virgil A. Place | Buccal drug delivery system for use in male contraception |
| TW200400041A (en) * | 2002-05-30 | 2004-01-01 | Akzo Nobel Nv | Use of new etonogestrel esters |
-
2003
- 2003-05-19 TW TW092113489A patent/TW200403065A/zh unknown
- 2003-05-22 CN CNA2007101028610A patent/CN101100480A/zh active Pending
- 2003-05-22 AT AT03735713T patent/ATE349458T1/de not_active IP Right Cessation
- 2003-05-22 US US10/516,402 patent/US7323454B2/en not_active Expired - Lifetime
- 2003-05-22 DE DE60310714T patent/DE60310714T2/de not_active Expired - Lifetime
- 2003-05-22 CA CA2487722A patent/CA2487722C/en not_active Expired - Fee Related
- 2003-05-22 RU RU2004138807/15A patent/RU2325910C2/ru not_active IP Right Cessation
- 2003-05-22 KR KR10-2004-7019330A patent/KR20050009723A/ko not_active Ceased
- 2003-05-22 DK DK03735713T patent/DK1513861T3/da active
- 2003-05-22 PT PT03735713T patent/PT1513861E/pt unknown
- 2003-05-22 SI SI200330679T patent/SI1513861T1/sl unknown
- 2003-05-22 ES ES03735713T patent/ES2277085T3/es not_active Expired - Lifetime
- 2003-05-22 BR BR0311254-3A patent/BR0311254A/pt not_active IP Right Cessation
- 2003-05-22 JP JP2004509703A patent/JP4716726B2/ja not_active Expired - Fee Related
- 2003-05-22 RS YU97604A patent/RS97604A/sr unknown
- 2003-05-22 MX MXPA04011797A patent/MXPA04011797A/es active IP Right Grant
- 2003-05-22 HR HRP20041101 patent/HRP20041101A2/xx not_active Application Discontinuation
- 2003-05-22 AU AU2003238081A patent/AU2003238081B2/en not_active Ceased
- 2003-05-22 WO PCT/EP2003/050187 patent/WO2003102012A2/en not_active Ceased
- 2003-05-22 EP EP03735713A patent/EP1513861B1/en not_active Expired - Lifetime
- 2003-05-22 PL PL03373855A patent/PL373855A1/xx unknown
- 2003-05-22 NZ NZ536619A patent/NZ536619A/en unknown
- 2003-05-22 CN CNB038123754A patent/CN1314701C/zh not_active Expired - Fee Related
- 2003-05-22 UA UA20041109287A patent/UA80126C2/uk unknown
- 2003-05-28 AR ARP030101859A patent/AR040130A1/es unknown
- 2003-05-28 PE PE2003000517A patent/PE20040068A1/es not_active Application Discontinuation
-
2004
- 2004-11-08 IL IL16508704A patent/IL165087A0/xx unknown
- 2004-11-10 NO NO20044898A patent/NO20044898L/no not_active Application Discontinuation
- 2004-11-15 IS IS7528A patent/IS2421B/is unknown
- 2004-12-22 CO CO04127949A patent/CO5631449A2/es not_active Application Discontinuation
- 2004-12-23 ZA ZA200410410A patent/ZA200410410B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2277085T3 (es) | Nuevos esteres de etonogestrel. | |
| FI88509B (fi) | 9-alfa,11-beta-nitro-substituerade och 11-beta-nitro-substituerade estraner | |
| HUP0102274A2 (hu) | Tesztoszteronszármazék és ezt tartalmazó gyógyszerkészítmény | |
| ES2305498T3 (es) | Uso de nuevos esteres de etonogestrel. | |
| ES2260294T3 (es) | 17-metilen-esteroides halogenados en posicion 4, procedimientos para su preparacion y composiciones que contienen estos compuestos. | |
| AU2006211907B2 (en) | Nandrolone 17beta-carbonates | |
| HK1072609B (en) | New etonogestrel esters | |
| ES2294569T3 (es) | Esteroides que tienen un perfil mixto androgenico y progestagenico. | |
| WO2020245641A1 (en) | Novel esters of medroxyprogesterone | |
| HK1072568B (en) | Use of new etonogestrel esters | |
| HRP20040193A2 (en) | 17alpha-hydroxy-14beta-steroids with hormonal effect | |
| MXPA00012805A (en) | Testosterone derivative | |
| WO2003053993A1 (en) | Androgenic 14.alpha, 17.alpha-ethenosteroids |